1Leone G, Pagano L, Ben-Yehuda D, et al.Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica, 2007, 92: 1389-1398.
2Yin CC, Glassman AB, Lin P, et al. Morphologic, cytogenetic, and molecular abnormalities in therapy-related acute promyeIocytic leukemia. Am J Clin Pathol, 2005, 123: 840-848.
4Hoffmann L, Moller P, Pedersen-Bjergaard J, et al. Therapy-related acute promydocytic leukemia with t (15;17)(q22;q12) following chemotherapy with drugs targeting DNA topoisomerase Ⅱ. A report of two cases and a review of the hterature. Ann Oncol, 1995, 6: 781-788.
5Kern W, Haferlach T, Schninger S, et al. Prognosis in therapy-related acute myeloid leukemia and impact of karyotype. J Clin Oncol, 2004, 22: 2510-2511.
6Joannides M, Grimwade D. Molecular biology of therapy-related leukaemias. Clin Transl Oncol, 2010, 12: 8-14.
7Duffield AS, Aoki J, Levis M, et al. Clinical and pathologic features of secondary acute promyelocytic leukemia. Am J Clin Pathol, 2012, 137: 395-402.
二级参考文献8
1Kroger N,Brand R,Van Biezen A,et al.Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplasticsyndrome[J],Bone Marrow Transplant,2006,37(2):183-189.
2Mochiduki Y,Muramoto S.Therapy-related acute promyelocytic leukemia with a t (9;22)(q34;q11) and t (15;17)(q22;q11 to approximately 12)subclone[J].Rinsho Ketsueki,2005,46(11):1218-1222.
3Ogami A,Morimoto A,Hibi S,et al.Secondary acute promyelocytic leukemia following chemotherapy for non-Hodgkin lymphoma in a child[J].J Pediatr Hematol Oncol,2004,26(7):427-430.
4Yin C C,Glassman A B,Lin P,et al.Morphologic,Cytogenetic,and molecular abnormalities in therapy-related acute promyelocytic leukemia[J].Am J Clin Pathol,2005,123(6):840-848.
5Rund D,Krichevsky S,Bar-Cohen S,et al.Therapy-related leukemia:clinical characteristics and analysis of new molecular risk factors in 96 adult patients[J].Leukemia,2005,19(11):1919-1928.
6Hosing C,Munsell M,Yazji S,et al.Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin lymphoma[J].Ann Oncol,2002,13(3):450-459.
7Krishnan A,Bhatia S,Slovak M L,et al.Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma:an assessment of risk factors[J].Blood,2000,95(5):1588-1593.
